bioMérieux is first and foremost a human and scientific adventure that began more than 55 years ago, yet its roots reach back to the tradition of Louis Pasteur and the fight against infectious diseases. In 1897, Marcel Mérieux, who had studied with Pasteur, founded a laboratory in Lyon where he developed the first anti-tetanus sera.
He called it , and from the outset began to lay the groundwork for a bio-industrial edifice that would leave its mark on vaccinology and the diagnosis of infectious diseases worldwide. Under the direction of his son, Dr. Charles Mérieux, and later his grandson, Alain Mérieux, Institut Mérieux grew to become world leader in human and veterinary vaccines. The Institute gave rise to companies that rank today as major players in public health, such as Sanofi Pasteur and Merial.
In 1994, Alain Mérieux shifted his focus from the vaccines activity to concentrate on the family holding and its diagnostics and immunotherapy businesses, including bioMérieux.
In 2014, Alexandre Mérieux, Marcel’s great-grandson, took up the torch and today continues the family tradition as CEO of bioMérieux. Then he was appointed Chairman and CEO by the Board of Directors in December 2017.